Saturday, January 11

Tag: Metabolic dysfunction

ESG Alone Offers Lasting Benefits for Obesity Comorbidities

ESG Alone Offers Lasting Benefits for Obesity Comorbidities

Health and Mediacal
TOPLINE:Endoscopic sleeve gastroplasty (ESG) as a standalone treatment is a safe and reliable minimally intrusive treatment that might assist attain substantial long-lasting weight reduction and continual enhancements in obesity-related comorbidities.APPROACH:Scientist carried out a 5-year potential accomplice research study to examine the long-lasting impacts of ESG as monotherapy on obesity-related comorbidities in 404 adult clients (suggest age, 45 years; 76.2% females) with a body mass index ≥ 30 or ≥ 27 with comorbidities who went through the treatment in between August 2013 and July 2024.Individuals had actually stopped working prior nonsurgical weight reduction efforts or picked not to go through surgical treatment in spite of being qualified for it.The main results were the impact...
‘A Watershed Moment’: GLP-1 Drug Succeeds in Late-Stage MASH Trial

‘A Watershed Moment’: GLP-1 Drug Succeeds in Late-Stage MASH Trial

Health and Mediacal
Meeting Coverage > > AASLD-- First favorable stage III research study for a GLP-1 agonist in persistent liver illness by Mike Bassett, Staff Writer, MedPage Today November 20, 2024 Semaglutide (Wegovy) enhanced liver fibrosis in clients with metabolic dysfunction-associated steatohepatitis (MASH) and resulted in higher rates of MASH resolution, an interim analysis of a stage III trial revealed. In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist led to greater week-72 rates of steatohepatitis resolution without getting worse of liver fibrosis (63% vs 34% with placebo) and enhancement in liver fibrosis without in...